Literature DB >> 33542712

Haplotype Motif-Based Models for KIR-Genotype Informed Selection of Hematopoietic Cell Donors Fail to Predict Outcome of Patients With Myelodysplastic Syndromes or Secondary Acute Myeloid Leukemia.

Johannes Schetelig1,2, Henning Baldauf2, Linda Koster3, Michelle Kuxhausen4, Falk Heidenreich1,2, Liesbeth C de Wreede2,5, Stephen Spellman4, Michel van Gelder6, Benedetto Bruno7, Francesco Onida8, Vinzenz Lange9, Carolin Massalski9, Victoria Potter10, Per Ljungman11, Nicolaas Schaap12, Patrick Hayden13, Stephanie J Lee14, Nicolaus Kröger15, Kathy Hsu16, Alexander H Schmidt2,9, Ibrahim Yakoub-Agha17, Marie Robin18.   

Abstract

Results from registry studies suggest that harnessing Natural Killer (NK) cell reactivity mediated through Killer cell Immunoglobulin-like Receptors (KIR) could reduce the risk of relapse after allogeneic Hematopoietic Cell Transplantation (HCT). Several competing models have been developed to classify donors as KIR-advantageous or disadvantageous. Basically, these models differ by grouping donors based on distinct KIR-KIR-ligand combinations or by haplotype motif assignment. This study aimed to validate different models for unrelated donor selection for patients with Myelodysplatic Syndromes (MDS) or secondary Acute Myeloid Leukemia (sAML). In a joint retrospective study of the European Society for Blood and Marrow Transplantation (EBMT) and the Center for International Blood and Marrow Transplant Research (CIBMTR) registry data from 1704 patients with secondary AML or MDS were analysed. The cohort consisted mainly of older patients (median age 61 years) with high risk disease who had received chemotherapy-based reduced intensity conditioning and anti-thymocyte globulin prior to allogeneic HCT from well-matched unrelated stem cell donors. The impact of the predictors on Overall Survival (OS) and relapse incidence was tested in Cox regression models adjusted for patient age, a modified disease risk index, performance status, donor age, HLA-match, sex-match, CMV-match, conditioning intensity, type of T-cell depletion and graft type. KIR genes were typed using high-resolution amplicon-based next generation sequencing. In univariable and multivariable analyses none of the models predicted OS and the risk of relapse consistently. Our results do not support the hypothesis that optimizing NK-mediated alloreactivity is possible by KIR-genotype informed selection of HLA-matched unrelated donors. However, in the context of allogeneic transplantation, NK-cell biology is complex and only partly understood. KIR-genes are highly diverse and current assignment of haplotype motifs based on the presence or absence of selected KIR genes is over-simplistic. As a consequence, further research is highly warranted and should integrate cutting edge knowledge on KIR genetics, and NK-cell biology into future studies focused on homogeneous groups of patients and treatment modalities.
Copyright © 2021 Schetelig, Baldauf, Koster, Kuxhausen, Heidenreich, de Wreede, Spellman, van Gelder, Bruno, Onida, Lange, Massalski, Potter, Ljungman, Schaap, Hayden, Lee, Kröger, Hsu, Schmidt, Yakoub-Agha and Robin.

Entities:  

Keywords:  KIR; KIR2DS1; KIR3DL1; donor selection; hematopoietic stem cell transplantation; unrelated donor

Mesh:

Substances:

Year:  2021        PMID: 33542712      PMCID: PMC7851088          DOI: 10.3389/fimmu.2020.584520

Source DB:  PubMed          Journal:  Front Immunol        ISSN: 1664-3224            Impact factor:   7.561


  47 in total

1.  Different NK cell surface phenotypes defined by the DX9 antibody are due to KIR3DL1 gene polymorphism.

Authors:  C M Gardiner; L A Guethlein; H G Shilling; M Pando; W H Carr; R Rajalingam; C Vilches; P Parham
Journal:  J Immunol       Date:  2001-03-01       Impact factor: 5.422

2.  Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes.

Authors:  Katharine C Hsu; Carolyn A Keever-Taylor; Andrew Wilton; Clara Pinto; Glenn Heller; Knarik Arkun; Richard J O'Reilly; Mary M Horowitz; Bo Dupont
Journal:  Blood       Date:  2005-02-24       Impact factor: 22.113

3.  Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia.

Authors:  Rizwan Romee; Maximillian Rosario; Melissa M Berrien-Elliott; Julia A Wagner; Brea A Jewell; Timothy Schappe; Jeffrey W Leong; Sara Abdel-Latif; Stephanie E Schneider; Sarah Willey; Carly C Neal; Liyang Yu; Stephen T Oh; Yi-Shan Lee; Arend Mulder; Frans Claas; Megan A Cooper; Todd A Fehniger
Journal:  Sci Transl Med       Date:  2016-09-21       Impact factor: 17.956

4.  Phase II Study of Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Myeloid Malignancies Following Allogeneic Hematopoietic Cell Transplantation.

Authors:  Brian C Shaffer; Jean-Benoit Le Luduec; Christopher Forlenza; Ann A Jakubowski; Miguel-Angel Perales; James W Young; Katharine C Hsu
Journal:  Biol Blood Marrow Transplant       Date:  2016-01-06       Impact factor: 5.742

5.  Donor-recipient combinations of group A and B KIR haplotypes and HLA class I ligand affect the outcome of HLA-matched, sibling donor hematopoietic cell transplantation.

Authors:  Karina L McQueen; Kristel M Dorighi; Lisbeth A Guethlein; Ruby Wong; Bharati Sanjanwala; Peter Parham
Journal:  Hum Immunol       Date:  2007-03-12       Impact factor: 2.850

6.  Inhibitory killer cell immunoglobulin-like receptors strengthen CD8+ T cell-mediated control of HIV-1, HCV, and HTLV-1.

Authors:  Lies Boelen; Bisrat Debebe; Marcos Silveira; Arafa Salam; Julia Makinde; Chrissy H Roberts; Eddie C Y Wang; John Frater; Jill Gilmour; Katie Twigger; Kristin Ladell; Kelly L Miners; Jyothi Jayaraman; James A Traherne; David A Price; Ying Qi; Maureen P Martin; Derek C Macallan; Chloe L Thio; Jacquie Astemborski; Gregory Kirk; Sharyne M Donfield; Susan Buchbinder; Salim I Khakoo; James J Goedert; John Trowsdale; Mary Carrington; Simon Kollnberger; Becca Asquith
Journal:  Sci Immunol       Date:  2018-11-09

7.  Plasticity in the organization and sequences of human KIR/ILT gene families.

Authors:  M J Wilson; M Torkar; A Haude; S Milne; T Jones; D Sheer; S Beck; J Trowsdale
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-25       Impact factor: 11.205

8.  Copy number variation leads to considerable diversity for B but not A haplotypes of the human KIR genes encoding NK cell receptors.

Authors:  Wei Jiang; Chris Johnson; Jyothi Jayaraman; Nikol Simecek; Janelle Noble; Miriam F Moffatt; William O Cookson; John Trowsdale; James A Traherne
Journal:  Genome Res       Date:  2012-09-04       Impact factor: 9.043

9.  Estimation of German KIR Allele Group Haplotype Frequencies.

Authors:  Ute V Solloch; Daniel Schefzyk; Gesine Schäfer; Carolin Massalski; Maja Kohler; Jens Pruschke; Annett Heidl; Johannes Schetelig; Alexander H Schmidt; Vinzenz Lange; Jürgen Sauter
Journal:  Front Immunol       Date:  2020-03-12       Impact factor: 7.561

10.  KIR B donors improve the outcome for AML patients given reduced intensity conditioning and unrelated donor transplantation.

Authors:  Daniel Weisdorf; Sarah Cooley; Tao Wang; Elizabeth Trachtenberg; Cynthia Vierra-Green; Stephen Spellman; Jennifer A Sees; Ashley Spahn; Jenny Vogel; Todd A Fehniger; Ann E Woolfrey; Steven M Devine; Maureen Ross; Edmund K Waller; Ronald M Sobecks; Joseph McGuirk; Betul Oran; Sherif S Farag; Tsiporah Shore; Koen Van Besien; Steven G E Marsh; Lisbeth A Guethlein; Peter Parham; Jeffrey S Miller
Journal:  Blood Adv       Date:  2020-02-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.